Zealand Pharma

Major Shareholding Notification • Apr 22, 2015

Copenhagen, 2015-04-22 22:41 CEST (GLOBE NEWSWIRE) -- Copenhagen, 22 April 2015
– Zealand Pharma (Nasdaq Copenhagen: ZEAL) (“Zealand”) has received a major
shareholder announcement from LSP III Omni Investment Coöperatief U.A. and LSP
III Management BV which exercises voting rights with respect to the shares,
which are held by LSP III Omni Investment Coöperafief U.A.

Pursuant to Section 29 of the Danish Securities Act, cf. executive order no.
668 of 25 June 2012 on major shareholders it has been reported that following
the increase in Zealand’s share capital on 21 March 2015, the 1,161,268 shares
held by LSP III Omni Investment Coöperatief U.A. corresponds to 4.98% of
Zealand's share capital. Following the increase in Zealand's share capital on
11 April 2015, the current holding percentage of LSP III Omni Investment
Coöperatief U.A. corresponds to 4.96% of Zealand's share capital.

Further, it has been reported that LSP III Management BV which takes investment
decisions and exercise voting rights with respect to the shares held by LSP III
Omni Investment Coöperatief U.A. now exercises voting rights for 4.96% of
Zealand's share capital.

                                  ?????

For further information, please contact:

Hanne Leth Hillman, Senior Vice President for Communications and Investor
Relations

Tel: +45 50 60 36 89, email: hlh@zealandpharma.com

About Zealand Pharma

Zealand Pharma A/S (“Zealand”) (Nasdaq Copenhagen: ZEAL) is a biotechnology
company based in Copenhagen, Denmark. Zealand has leading expertise in the
discovery, design and development of novel peptide medicines and possesses
in-house competences in clinical trial design and management with a therapeutic
focus on metabolic diseases and acute care indications. The company is
advancing a proprietary pipeline of novel medicines alongside a partnered
product and development portfolio.

Zealand’s first invented medicine, lixisenatide, a once-daily prandial GLP-1
agonist for the treatment of Type 2 diabetes, is marketed globally (ex-US) as
Lyxumia® and in Phase III development as a single-injection combination with
Lantus® (LixiLan), both under a global license agreement with Sanofi. US
regulatory submission of Lyxumia® is planned for Q3 2015 and US/EU regulatory
submissions for LixiLan in Q4 2015.

Zealand proprietary pipeline includes danegaptide (prevention of Ischemic
Reperfusion Injury) and the stable glucagon product, ZP4207 (treatment of
severe hypoglycemia) as well as several preclinical peptide therapeutics.
Partnering represents an important component of strategy to leverage in-house
expertise, share development risk in large clinical trials, provide funding and
commercialize the company’s products. Zealand currently has global license
agreements and partnerships with Sanofi, Helsinn Healthcare, Boehringer
Ingelheim and Eli Lilly.

For further information: www.zealandpharma.com Follow us on Twitter
@ZealandPharma